- TruePrime(TM) RCA kit for rolling circle amplification represents the third product of SYGNIS’ proprietary TruePrime(TM) product family
- TruePrime(TM) RCA kit opens up a new field of applications in recombinant protein production and molecular cloning
- SYGNIS successfully execute product and commercialization strategy
> Madrid, Spain and Heidelberg, Germany, June 8th, 2015 - SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today announced the global launch of TruePrime(TM) RCA kit, the third product of its TruePrime(TM) product line for the amplification of circular DNA targets.
SYGNIS TruePrime(TM) product family covers a series of kits for the amplification of DNA and RNA from biological samples. Based on the combination of SYGNIS’ proprietary DNA primase TthPrimPol with its Phi29 polymerase, the TruePrime(TM) technology does not need any synthetic random primers unlike current standard technologies in DNA amplification which need short pieces of DNA (“oligonucleotides”) to start the reaction.
The newly launched TruePrime(TM) RCA kit is designed and optimized for the amplification of circular nucleic acids. RCA stands for “rolling circle amplification”, which refers to the ability to rapidly synthesize multiple copies of circular molecules of DNA and RNA from smallest amounts of samples such as plasmids from single bacterial colonies, liquid culture or glycerol stock as well as genomes of bacteriophages (cosmids) or the circular RNA genome of viroids.
One of the most common work steps in every molecular biology lab around the globe is the growing and isolation of small circular pieces of DNA, so-called plasmids that are the main working tool for manipulating genetic information. SYGNIS’ new TruePrime(TM) RCA kit has superior features that allow a significant reduction in these steps by enabling direct amplification of plasmids from purified DNA or bacteria. Furthermore it brings down the work and time involved in this standard process from 18 to just one hour. This represents an important process optimization that can speed up important research projects for today’s busy researchers. Additionally, the TruePrime(TM) RCA kit can be used to amplify large circular vectors such as BACs and cosmids needed for genetic manipulation.
Based on the Company’s proprietary TruePrime(TM) technology, TruePrime(TM) RCA kit shares the superior advantages of the other products of the TruePrime(TM) family already launched including the complete absence of common artifacts linked to the use of oligonucleotides. Furthermore, these advantages include: the reduced amplification bias in genome coverage, outstanding reliability as the technology is insensitive to external DNA contaminations, a high reproducibility, plus a superior sensitivity and ease of use.
“Our TruePrime(TM) product family continuously expands. This is now the third launch of a new product reported for our TruePrime(TM) product line within just six months, addressing key challenges in many areas of molecular biology today,” Pilar de la Huerta, CEO/CFO of SYGNIS AG commented . “With the new TruePrime(TM) RCA kit, we have launched a product providing significant advantages over currently available technologies for rolling circle amplification. This product has the potential to further simplify processes and thus to significantly increase the efficiency of workflows. We are convinced that this kit will receive the same high attention from the research community as we already have seen with all our other launched products.”
The TruePrime(TM) RCA kit is in stock and will be globally commercialized through distributors and the SYGNIS online shop under www.sygnis.com/shop. TruePrime(TM) RCA kit is available in a format, containing 100 reactions.
SYGNIS has started an extensive promotional mailing campaign to all potential users in the molecular biology field. The Company plans a wide range of additional marketing events around the product launch including presentations at key international scientific meetings and conferences including the currently held European Society of Human Genetics (ESHG) in Glasgow and the upcoming BIO International Convention in Philadelphia, USA.
SYGNIS is currently developing a series of additional TruePrime(TM) kits for a variety of applications that are expected to be launched throughout 2015 and 2016.
About TruePrime(TM)
TruePrime(TM) is the brand name of a revolutionary novel MDA technology and one of the key products in SYGNIS’ portfolio. TruePrime(TM) is based on the combination of SYGNIS proprietary DNA primase “TthPrimPol” and the extremely processive and high-fidelity Phi29 polymerase to amplify uniformly total genomic DNA for a multitude of applications including next generation sequencing and single cell analysis. The extraordinary strand displacement capacity of the Phi29 polymerase allows TthPrimPol to generate new primers on the displaced strands that are extended by Phi29 DNA pol, resulting in exponential isothermal DNA amplification without the need of any synthetic random primers.
For further information please contact:
SYGNIS AG
Pilar de la Huerta
CEO/CFO
Phone: +34 91 192 36 50
Email: pdelahuerta@sygnis.com
MC Services AG
Raimund Gabriel
Managing Partner
Phone: +49 89 210228 30
Email: raimund.gabriel@mc-services.eu
Following the merger with X-Pol Biotech in 2012, SYGNIS specializes on the development and commercialization of products for DNA amplification and sequencing. SYGNIS AG, listed at the German Stock Exchange (Prime Standard segment, Tick: LIO1; ISIN: DE000A1RFM03), has a commercial product for whole genome DNA amplification, SensiPhi (R) , licensed to an industry leading partner and two own product lines on the market: TruePrime(TM) based on its proprietary TruePrime(TM) technology for whole genome amplification and SunScript(TM) Reverse Transcriptase to convert genetic information from RNA molecules back to DNA. Both product lines are addressing key challenges in the fast growing fields of molecular biology and next generation sequencing applications.
Help employers find you! Check out all the jobs and post your resume.
